CA2806233C - Transgenic animals and methods of use - Google Patents

Transgenic animals and methods of use Download PDF

Info

Publication number: CA2806233C
Authority: CA; Canada
Prior art keywords: human; cell; variable region; mouse; locus
Prior art date: 2010-07-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2806233A

Other languages

English (en)

French (fr)

Other versions

CA2806233A1 (en

Inventor

Matthias Wabl

Nigel Killeen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Trianni Inc

Original Assignee

Trianni Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-26

Filing date

2011-07-26

Publication date

2021-12-07

2011-07-26 Application filed by Trianni Inc filed Critical Trianni Inc

2012-02-09 Publication of CA2806233A1 publication Critical patent/CA2806233A1/en

2021-12-07 Application granted granted Critical

2021-12-07 Publication of CA2806233C publication Critical patent/CA2806233C/en

Status Active legal-status Critical Current

2031-07-26 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims description 113
230000009261 transgenic effect Effects 0.000 title claims description 36
241001465754 Metazoa Species 0.000 title description 28
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 148
102000018358 immunoglobulin Human genes 0.000 claims abstract description 148
210000004027 cell Anatomy 0.000 claims description 220
238000005215 recombination Methods 0.000 claims description 153
230000006798 recombination Effects 0.000 claims description 152
108090000623 proteins and genes Proteins 0.000 claims description 148
239000013598 vector Substances 0.000 claims description 147
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 102
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 96
230000008685 targeting Effects 0.000 claims description 77
108010091086 Recombinases Proteins 0.000 claims description 66
102000018120 Recombinases Human genes 0.000 claims description 66
150000007523 nucleic acids Chemical group 0.000 claims description 40
238000011830 transgenic mouse model Methods 0.000 claims description 39
108020004707 nucleic acids Proteins 0.000 claims description 38
102000039446 nucleic acids Human genes 0.000 claims description 38
101150008942 J gene Proteins 0.000 claims description 37
238000011144 upstream manufacturing Methods 0.000 claims description 29
238000012217 deletion Methods 0.000 claims description 27
230000037430 deletion Effects 0.000 claims description 27
210000003719 b-lymphocyte Anatomy 0.000 claims description 25
230000001404 mediated effect Effects 0.000 claims description 23
108010052160 Site-specific recombinase Proteins 0.000 claims description 21
108091026890 Coding region Proteins 0.000 claims description 19
108091092195 Intron Proteins 0.000 claims description 14
108700005091 Immunoglobulin Genes Proteins 0.000 claims description 13
230000001105 regulatory effect Effects 0.000 claims description 13
101150097493 D gene Proteins 0.000 claims description 11
101150117115 V gene Proteins 0.000 claims description 9
108700024394 Exon Proteins 0.000 claims description 8
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 7
239000000427 antigen Substances 0.000 claims description 5
108091007433 antigens Proteins 0.000 claims description 5
102000036639 antigens Human genes 0.000 claims description 5
230000000717 retained effect Effects 0.000 claims description 2
102000012745 Immunoglobulin Subunits Human genes 0.000 claims 3
108010079585 Immunoglobulin Subunits Proteins 0.000 claims 3
102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
238000003491 array Methods 0.000 claims 2
101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 claims 1
102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 claims 1
238000010367 cloning Methods 0.000 claims 1
241000699666 Mus <mouse, genus> Species 0.000 description 111
108020004414 DNA Proteins 0.000 description 95
241000699670 Mus sp. Species 0.000 description 37
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 30
238000003752 polymerase chain reaction Methods 0.000 description 23
229930193140 Neomycin Natural products 0.000 description 20
229960004927 neomycin Drugs 0.000 description 20
108010051219 Cre recombinase Proteins 0.000 description 19
238000002105 Southern blotting Methods 0.000 description 19
108700026244 Open Reading Frames Proteins 0.000 description 18
239000000523 sample Substances 0.000 description 18
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 15
229950010131 puromycin Drugs 0.000 description 15
238000003556 assay Methods 0.000 description 14
238000002744 homologous recombination Methods 0.000 description 14
230000006801 homologous recombination Effects 0.000 description 14
230000035772 mutation Effects 0.000 description 14
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 13
229960002963 ganciclovir Drugs 0.000 description 13
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 12
241000124008 Mammalia Species 0.000 description 12
230000008569 process Effects 0.000 description 12
238000010363 gene targeting Methods 0.000 description 11
210000004602 germ cell Anatomy 0.000 description 11
239000003550 marker Substances 0.000 description 11
108020004440 Thymidine kinase Proteins 0.000 description 10
210000000349 chromosome Anatomy 0.000 description 10
238000010586 diagram Methods 0.000 description 10
239000003814 drug Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108020004705 Codon Proteins 0.000 description 8
101500025336 Homo sapiens Heparin-binding EGF-like growth factor Proteins 0.000 description 8
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
241000251539 Vertebrata <Metazoa> Species 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
238000013461 design Methods 0.000 description 8
239000012634 fragment Substances 0.000 description 8
210000004962 mammalian cell Anatomy 0.000 description 8
229930182817 methionine Natural products 0.000 description 8
230000008488 polyadenylation Effects 0.000 description 8
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 8
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
230000005030 transcription termination Effects 0.000 description 8
108010046276 FLP recombinase Proteins 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
230000013011 mating Effects 0.000 description 7
238000001890 transfection Methods 0.000 description 7
241000271566 Aves Species 0.000 description 6
102000016607 Diphtheria Toxin Human genes 0.000 description 6
108010053187 Diphtheria Toxin Proteins 0.000 description 6
241000700584 Simplexvirus Species 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
238000012216 screening Methods 0.000 description 6
230000014621 translational initiation Effects 0.000 description 6
108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
108700019146 Transgenes Proteins 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
208000031404 Chromosome Aberrations Diseases 0.000 description 4
108091035707 Consensus sequence Proteins 0.000 description 4
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
102100029572 Immunoglobulin kappa constant Human genes 0.000 description 4
108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 4
101000579126 Mus musculus Phosphoglycerate kinase 1 Proteins 0.000 description 4
241001045988 Neogene Species 0.000 description 4
241001505332 Polyomavirus sp. Species 0.000 description 4
238000011529 RT qPCR Methods 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
231100000005 chromosome aberration Toxicity 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
239000003999 initiator Substances 0.000 description 4
238000013507 mapping Methods 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
101150091879 neo gene Proteins 0.000 description 4
229960003087 tioguanine Drugs 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
238000011765 DBA/2 mouse Methods 0.000 description 3
102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 3
108010061833 Integrases Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
238000002944 PCR assay Methods 0.000 description 3
230000004075 alteration Effects 0.000 description 3
210000002459 blastocyst Anatomy 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000010354 integration Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
102000053602 DNA Human genes 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
238000012442 analytical experiment Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 description 1
102000012330 Integrases Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000701955 Streptomyces virus phiC31 Species 0.000 description 1
101150073538 V1 gene Proteins 0.000 description 1
101150000889 V2 gene Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005021 gait Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000006713 insertion reaction Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000006780 non-homologous end joining Effects 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Environmental Sciences (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Animal Husbandry (AREA)
Physics & Mathematics (AREA)
Biodiversity & Conservation Biology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA2806233A 2010-07-26 2011-07-26 Transgenic animals and methods of use Active CA2806233C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36780910P	2010-07-26	2010-07-26
US61/367,809		2010-07-26
PCT/US2011/045333 WO2012018610A2 (en)	2010-07-26	2011-07-26	Transgenic animals and methods of use

Publications (2)

Publication Number	Publication Date
CA2806233A1 CA2806233A1 (en)	2012-02-09
CA2806233C true CA2806233C (en)	2021-12-07

Family

ID=45559986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2806233A Active CA2806233C (en)	2010-07-26	2011-07-26	Transgenic animals and methods of use

Country Status (11)

Country	Link
US (2)	US10881084B2 (2)
EP (1)	EP2597945B1 (2)
JP (4)	JP6482757B2 (2)
KR (1)	KR20130097156A (2)
CN (1)	CN103025884B (2)
AU (1)	AU2011286185B2 (2)
CA (1)	CA2806233C (2)
DK (1)	DK2597945T3 (2)
IL (1)	IL224327B (2)
RU (1)	RU2580017C2 (2)
WO (1)	WO2012018610A2 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2984483T3 (es) *	2010-03-31	2024-10-29	Ablexis Llc	Ingeniería genética de ratones para la producción de anticuerpos quiméricos
US10793829B2 (en)	2010-07-26	2020-10-06	Trianni, Inc.	Transgenic mammals and methods of use thereof
CN103025884B (zh) *	2010-07-26	2015-11-25	特里安尼公司	转基因动物和使用方法
US10662256B2 (en)	2010-07-26	2020-05-26	Trianni, Inc.	Transgenic mammals and methods of use thereof
CN107858333B (zh)	2011-10-28	2022-05-27	瑞泽恩制药公司	T细胞受体基因修饰小鼠
EP3699190B9 (en)	2013-02-22	2023-10-04	Regeneron Pharmaceuticals, Inc.	Murine cell expressing humanized major histocompatibility complex
JP2018525007A (ja)	2015-08-24	2018-09-06	トリアンニインコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ．	免疫グロブリンの産生増強
US10813346B2 (en)	2015-12-03	2020-10-27	Trianni, Inc.	Enhanced immunoglobulin diversity
EP4414484A3 (en)	2016-02-04	2025-01-15	Trianni, Inc.	Enhanced production of immunoglobulins
KR102483193B1 (ko)	2016-06-03	2023-01-04	리제너론 파마슈티칼스 인코포레이티드	외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
GB2561352B (en) *	2017-04-10	2023-01-18	Genome Res Ltd	Animal models and therapeutic molecules
EP3625250B1 (en)	2017-07-21	2021-04-14	Trianni, Inc.	Single chain vh and heavy chain antibodies
DK3476942T3 (da)	2017-10-27	2022-04-19	Trianni Inc	Lange kimlinje-dh-gener og antistoffer med lang hcdr3
EP3772927B1 (en)	2018-03-24	2025-01-15	Regeneron Pharmaceuticals, Inc.	Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL318469A (en)	2018-06-14	2025-03-01	Regeneron Pharma	Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US20200109422A1 (en) *	2018-10-09	2020-04-09	Regents Of The University Of Minnesota	Methods of full gene replacement and transgenic non-human cells comprising full human genes
CA3125380A1 (en)	2019-02-18	2020-08-27	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Genetically modified non-human animals with humanized immunoglobulin locus
EP3978607B1 (en) *	2019-05-27	2025-08-20	Transgenic Inc.	Exon-humanized mouse
CN114502725B (zh) *	2019-07-01	2025-09-12	特里安尼公司	转基因哺乳动物及使用方法
DK3993623T3 (da) *	2019-07-01	2025-05-26	Zoetis Services Llc	Transgene gnavere og fremgangsmåder til anvendelse deraf
EP3785536B2 (en)	2019-08-28	2025-09-17	Trianni, Inc.	Adam6 knockin mice
US20220409732A1 (en)	2019-12-02	2022-12-29	Regeneron Pharmaceuticals, Inc.	Peptide-mhc ii protein constructs and uses thereof
JP2023529846A (ja)	2020-06-02	2023-07-12	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
WO2021261620A1 (ko) *	2020-06-25	2021-12-30	주식회사 휴맵	이형접합성 형질전환 동물
WO2022023292A2 (en)	2020-07-31	2022-02-03	Friedrich-Alexander-Universität Erlangen-Nürnberg	Corona virus spike protein-targeting antibodies and use thereof
US20220090060A1 (en)	2020-09-11	2022-03-24	Regeneron Pharmaceuticals, Inc.	Identification and production of antigen-specific antibodies
JP7822400B2 (ja)	2020-12-09	2026-03-02	トリアンニ，インコーポレーテッド	重鎖のみ抗体
CN116848254B (zh)	2020-12-16	2026-03-17	瑞泽恩制药公司	表达人源化Fcα受体的小鼠
CA3165366A1 (en)	2020-12-23	2022-06-30	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding anchor modified antibodies and uses thereof
CN114763558B (zh) *	2021-01-14	2024-02-20	上海泰槿生物技术有限公司	重组基因组、非人哺乳动物细胞及其产生方法和用途
CN118511853A (zh)	2021-03-31	2024-08-20	瑞泽恩制药公司	包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
WO2022235759A1 (en) *	2021-05-05	2022-11-10	Trianni, Inc.	Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof
US20250320520A1 (en)	2021-10-01	2025-10-16	Abcellera Biologics Inc.	Trangenic rodents for cell line identification and enrichment
JP7748680B2 (ja) *	2021-11-16	2025-10-03	国立大学法人鳥取大学	改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2026030428A2 (en)	2024-08-01	2026-02-05	Regeneron Pharmaceuticals, Inc.	Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en)	2024-08-06	2026-02-12	Regeneron Pharmaceuticals, Inc.	Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1293460C (en)	1985-10-07	1991-12-24	Brian Lee Sauer	Site-specific recombination of dna in yeast
US4892824A (en)	1988-03-15	1990-01-09	Synbiotics Corporation	Fast track method for producing monoclonal bi-specific immunoglobulins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8904009D0 (en)	1989-02-22	1989-04-05	Celltech Ltd	Vector
US5464764A (en)	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US6689610B1 (en)	1989-08-22	2004-02-10	University Of Utah Research Foundation	Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de)	1990-08-29	2007-03-15	Pharming Intellectual Pty Bv	Homologe rekombination in säugetier-zellen
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1992015694A1 (en)	1991-03-08	1992-09-17	The Salk Institute For Biological Studies	Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
DE4228162C1 (de)	1992-08-25	1994-01-13	Rajewsky Klaus Dr	Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
CZ140195A3 (en) *	1992-12-01	1996-06-12	Protein Desing Labs	Humanized antibodies reacting with l-selectin
JPH08509612A (ja)	1993-04-26	1996-10-15	ジェンファームインターナショナルインコーポレイテッド	異種抗体を産生することができるトランスジェニック非ヒト動物
US6084067A (en)	1993-07-26	2000-07-04	Dana-Farber Cancer Institute	CTLA4/CD28 ligands and uses therefor
US5593598A (en)	1994-04-20	1997-01-14	Mcginness; Michael P.	Method and apparatus for closed loop recycling of contaminated cleaning solution
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
DE19632532A1 (de)	1996-08-13	1998-02-19	Boehringer Ingelheim Int	Verfahren zur Herstellung von Säugetieren mit definierten genetischen Eigenschaften
CA2722378C (en)	1996-12-03	2015-02-03	Amgen Fremont Inc.	Human antibodies that bind tnf.alpha.
US6774279B2 (en)	1997-05-30	2004-08-10	Carnegie Institution Of Washington	Use of FLP recombinase in mice
TWI255853B (en)	1998-08-21	2006-06-01	Kirin Brewery	Method for modifying chromosomes
GB9823930D0 (en)	1998-11-03	1998-12-30	Babraham Inst	Murine expression of human ig\ locus
MXPA02000962A (es)	1999-07-29	2002-07-02	Medarex Inc	Anticuerpos monoclonales humanos para her2/neu.
EA013564B1 (ru)	2000-08-03	2010-06-30	Терапеутик Хьюман Поликлоналз Инк.	Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
FR2814642B1 (fr)	2000-10-03	2005-07-01	Ass Pour Le Dev De La Rech En	Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6586251B2 (en)	2000-10-31	2003-07-01	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20050144655A1 (en)	2000-10-31	2005-06-30	Economides Aris N.	Methods of modifying eukaryotic cells
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
WO2002066618A1 (en)	2001-02-20	2002-08-29	University Of Georgia Research Foundation, Inc.	Rapid production of monoclonal antibodies
CN1789416B (zh)	2001-05-11	2011-11-16	协和发酵麒麟株式会社	含人抗体λ轻链基因的人类人工染色体
US7473557B2 (en)	2001-06-06	2009-01-06	Regeneron Pharmaceuticals, Inc.	Method for targeting transcriptionally active loci
GB0115256D0 (en)	2001-06-21	2001-08-15	Babraham Inst	Mouse light chain locus
US7145057B2 (en)	2002-02-01	2006-12-05	Origen Therapeutics, Inc.	Chimeric bird from embryonic stem cells
US7323618B2 (en)	2002-02-01	2008-01-29	Origen Therapeutics, Inc.	Tissue specific expression of exogenous proteins in transgenic chickens
GB2398784B (en) *	2003-02-26	2005-07-27	Babraham Inst	Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US7205148B2 (en)	2003-06-11	2007-04-17	Regeneron Pharmaceuticals, Inc.	Genome mutation by intron insertion into an embryonic stem cell genome
DE10333239A1 (de)	2003-07-21	2005-03-10	Basf Ag	Verfahren zur Herstellung von gereinigten 1,3- substituierten Imidazoliumsalzen
ES2463476T3 (es)	2004-10-19	2014-05-28	Regeneron Pharmaceuticals, Inc.	Método para generar un ratón homocigótico para una modificación genética
US7422889B2 (en)	2004-10-29	2008-09-09	Stowers Institute For Medical Research	Dre recombinase and recombinase systems employing Dre recombinase
AU2007235496B2 (en)	2006-03-31	2013-11-21	E. R. Squibb & Sons, L.L.C.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2008070367A2 (en)	2006-11-01	2008-06-12	Facet Biotech Corporation	Mammalian cell-based immunoglobulin display libraries
GB0700194D0 (en) *	2007-01-05	2007-02-14	Univ Edinburgh	Humanisation of animals
PL2602323T3 (pl)	2007-06-01	2018-06-29	Open Monoclonal Technology, Inc.	Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
WO2009013620A2 (en)	2007-06-11	2009-01-29	Erasmus University Medical Center Rotterdam	Homologous recombination
JP5588866B2 (ja)	2007-08-10	2014-09-10	メダレックスエル．エル．シー．	Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US7947495B2 (en)	2007-11-01	2011-05-24	Abbott Biotherapeutics Corp.	Immunoglobulin display vectors
EP2147594B1 (en)	2008-06-27	2013-11-13	Merus B.V.	Antibody producing non-human mammals
AU2009298458B2 (en)	2008-09-30	2015-10-08	Ablexis, Llc	Non-human mammals for the production of chimeric antibodies
US20100317539A1 (en)	2009-06-12	2010-12-16	Guo-Liang Yu	Library of Engineered-Antibody Producing Cells
DK3622815T3 (da)	2009-07-08	2023-06-26	Kymab Ltd	Gnavermodeller og terapeutiske molekyler
ES2724975T3 (es)	2009-12-10	2019-09-18	Regeneron Pharma	Ratones que producen anticuerpos de cadena pesada
ES2984483T3 (es)	2010-03-31	2024-10-29	Ablexis Llc	Ingeniería genética de ratones para la producción de anticuerpos quiméricos
CN103228130B (zh)	2010-06-17	2016-03-16	科马布有限公司	动物模型及治疗分子
PT3034608T (pt)	2010-06-22	2019-05-28	Regeneron Pharma	Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
US10793829B2 (en)	2010-07-26	2020-10-06	Trianni, Inc.	Transgenic mammals and methods of use thereof
CN103025884B (zh)	2010-07-26	2015-11-25	特里安尼公司	转基因动物和使用方法
US10662256B2 (en)	2010-07-26	2020-05-26	Trianni, Inc.	Transgenic mammals and methods of use thereof
SMT201700023T1 (it)	2010-08-02	2017-03-08	Regeneron Pharma	Topi che producono proteine leganti vl
IN2013MN01438A (2)	2011-03-17	2015-06-12	Univ Ramot
HUE047278T2 (hu)	2011-08-05	2020-04-28	Regeneron Pharma	Humanizált univerzális könnyûláncú egerek
US20140283153A1 (en)	2011-10-28	2014-09-18	Trianni, Inc.	Transgenic animals and methods of use
GB2504139B (en)	2012-07-20	2014-12-31	Argen X Bv	Antibodies to highly conserved targets produced by the immunisation of Camelidae species
US9253965B2 (en)	2012-03-28	2016-02-09	Kymab Limited	Animal models and therapeutic molecules
SG10201605675WA (en)	2011-12-20	2016-09-29	Regeneron Pharma	Humanized light chain mice
CN104011080B (zh)	2011-12-22	2017-10-20	弗·哈夫曼-拉罗切有限公司	用于真核细胞的全长抗体展示系统及其用途
WO2013138681A1 (en)	2012-03-16	2013-09-19	Regeneron Pharmaceuticals, Inc.	Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
ME03551B (me)	2012-06-12	2020-07-20	Regeneron Pharma	Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
JPWO2014021240A1 (ja)	2012-08-03	2016-07-21	国立研究開発法人産業技術総合研究所	プロテインｇの細胞膜外ドメイン変異体のタンデム型多量体から成るタンパク質を含む捕捉剤
US10034463B2 (en)	2014-01-24	2018-07-31	Children's Medical Center Corporation	High-throughput mouse model for optimizing antibody affinities
EP4166148B1 (en)	2014-06-06	2026-02-18	Memorial Sloan-Kettering Cancer Center	Mesothelin-targeted chimeric antigen receptors and uses thereof
JP2018525007A (ja)	2015-08-24	2018-09-06	トリアンニインコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ．	免疫グロブリンの産生増強
US10813346B2 (en)	2015-12-03	2020-10-27	Trianni, Inc.	Enhanced immunoglobulin diversity
EP4414484A3 (en)	2016-02-04	2025-01-15	Trianni, Inc.	Enhanced production of immunoglobulins
SG10201913483XA (en)	2016-11-04	2020-03-30	Regeneron Pharma	Non-human animals having an engineered immunoglobulin lambda light chain locus
GB2561352B (en)	2017-04-10	2023-01-18	Genome Res Ltd	Animal models and therapeutic molecules
HUE060608T2 (hu)	2017-12-05	2023-03-28	Regeneron Pharma	Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása

2011
- 2011-07-26 CN CN201180036683.0A patent/CN103025884B/zh active Active
- 2011-07-26 JP JP2013521899A patent/JP6482757B2/ja active Active
- 2011-07-26 EP EP11815063.0A patent/EP2597945B1/en active Active
- 2011-07-26 WO PCT/US2011/045333 patent/WO2012018610A2/en not_active Ceased
- 2011-07-26 RU RU2013108269/10A patent/RU2580017C2/ru active
- 2011-07-26 AU AU2011286185A patent/AU2011286185B2/en active Active
- 2011-07-26 DK DK11815063.0T patent/DK2597945T3/da active
- 2011-07-26 CA CA2806233A patent/CA2806233C/en active Active
- 2011-07-26 US US13/818,184 patent/US10881084B2/en active Active
- 2011-07-26 KR KR1020137003807A patent/KR20130097156A/ko not_active Ceased
2013
- 2013-01-20 IL IL224327A patent/IL224327B/en active IP Right Grant
2017
- 2017-04-26 JP JP2017087115A patent/JP2017123880A/ja active Pending
2019
- 2019-03-12 JP JP2019044350A patent/JP6801030B2/ja active Active
2020
- 2020-10-22 US US17/077,545 patent/US12096753B2/en active Active
- 2020-11-25 JP JP2020194804A patent/JP2021027840A/ja active Pending

Also Published As

Publication number	Publication date
US20130219535A1 (en)	2013-08-22
AU2011286185A1 (en)	2013-02-14
KR20130097156A (ko)	2013-09-02
JP6482757B2 (ja)	2019-03-13
RU2013108269A (ru)	2014-09-10
AU2011286185B2 (en)	2014-08-14
JP2019083823A (ja)	2019-06-06
JP2013535202A (ja)	2013-09-12
WO2012018610A3 (en)	2012-05-03
EP2597945A4 (en)	2014-01-01
US10881084B2 (en)	2021-01-05
EP2597945B1 (en)	2020-07-22
CN103025884B (zh)	2015-11-25
JP2021027840A (ja)	2021-02-25
WO2012018610A2 (en)	2012-02-09
EP2597945A2 (en)	2013-06-05
IL224327B (en)	2018-04-30
DK2597945T3 (da)	2020-09-21
US20210037799A1 (en)	2021-02-11
US12096753B2 (en)	2024-09-24
CA2806233A1 (en)	2012-02-09
CN103025884A (zh)	2013-04-03
JP6801030B2 (ja)	2020-12-16
JP2017123880A (ja)	2017-07-20
RU2580017C2 (ru)	2016-04-10

Legal Events

Date	Code	Title	Description
2013-03-03	EEER	Examination request	Effective date: 20130121